Pharmaceutical compositions comprising meloxicam
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T max of meloxicam of 3 hours or less.
1. A method of treating migraine, comprising orally administering a combination of a meloxicam and a rizatriptan to a human being in need thereof, wherein the human being is experiencing migraine, and wherein the combination contains about 20 mg of meloxicam free acid, or a molar equivalent amount of a salt form of meloxicam, and about 8 mg to about 13 mg of rizatriptan free base, or a molar equivalent amount of a salt form of rizatriptan, wherein the meloxicam is complexed with a sulfobutylether-β-cyclodextrin, and wherein the combination further comprises a bicarbonate.
2. The method of claim 1 , wherein the human being experiences a reduction in migraine pain at 30 minutes after the combination of the meloxicam and the rizatriptan is orally administered.
3. The method of claim 1 , wherein the human being experiences a reduction in migraine pain at 60 minutes after the combination of the meloxicam and the rizatriptan is orally administered.
4. The method of claim 1 , wherein the human being experiences a reduction in migraine pain at 90 minutes after the combination of the meloxicam and the rizatriptan is orally administered.
5. The method of claim 4 , wherein the human being experiences a reduction in migraine pain at 24 hours after the combination of the meloxicam and the rizatriptan is orally administered.
6. The method of claim 1 , wherein the human being experiences freedom from the human being's most bothersome migraine-associated symptom at two hours after the combination is orally administered.
7. The method of claim 6 , wherein the human being's most bothersome migraine-associated symptom is selected from the group consisting of nausea, photophobia, and phonophobia.
8. The method of claim 1 , wherein migraine is associated with an aura.
9. The method of claim 1 , wherein the human being has reduced use of rescue medication after the combination of the meloxicam and the rizatriptan is orally administered.
10. The method of claim 1 , wherein the human being does not use rescue medication after the combination of the meloxicam and the rizatriptan is orally administered.
11. The method of claim 1 , wherein the human being is about 30% to about 50% less likely, as compared to placebo, to use rescue medication for the first 24 hours after the combination of the meloxicam and the rizatriptan is orally administered.
12. The method of claim 1 , wherein the human being achieves sustained pain freedom by two hours after the combination of the meloxicam and the rizatriptan is orally administered.
13. The method of claim 1 , wherein the human being achieves sustained pain freedom by two hours after the combination of the meloxicam and the rizatriptan is orally administered, and wherein the pain freedom continues for at least 24 hours.
14. The method of claim 1 , wherein the human being achieves sustained pain freedom by two hours after the combination of the meloxicam and the rizatriptan is orally administered, and wherein the pain freedom continues for at least 48 hours.
15. The method of claim 1 , wherein the human being achieves the ability to perform normal activities at 24 hours after the combination of the meloxicam and the rizatriptan is orally administered.
16. The method of claim 1 , wherein the combination of the meloxicam and the rizatriptan is in a dosage form, and wherein the dosage form has the property that administering the dosage form to a healthy human subject under fasted conditions results in the T max of meloxicam that is two hours or less.
17. The method of claim 1 , wherein the combination of the meloxicam and the rizatriptan is in a dosage form, and wherein the dosage form has the property that administering the dosage form to a healthy human subject under fasted conditions results in the T max of meloxicam that is one hour or less.